Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Rodríguez-Arbolí, Eduardo
96  Ergebnisse:
Personensuche X
?
1

Optimal Prognostic Threshold for Acute Myeloid Leukemia (AM..:

Rodríguez-Arbolí, Eduardo ; Othus, Megan ; Freeman, Sylvie...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S9 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Chimeric antigen receptor (CAR) modified T Cells in acute m..:

Guijarro-Albaladejo, Beatriz ; Marrero-Cepeda, Cristina ; Rodríguez-Arbolí, Eduardo...
Frontiers in Cell and Developmental Biology.  12 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
3

Preclinical Characterization of the Anti-Leukemia Activity ..:

Lunn-Halbert, Margaret C. ; Laszlo, George S. ; Erraiss, Sarah...
Cancers.  16 (2024)  5 - p. 877 , 2024
Link: https://doi.org/10.3390/..
 
?
4

Impact of socioeconomic disparities on outcomes in adults u..:

Olivieri, Daniel J. ; Othus, Megan ; Orvain, Corentin...
Leukemia.  38 (2024)  4 - p. 865-876 , 2024
Link: https://doi.org/10.1038/..
 
?
5

Second Allogeneic Hematopoietic Cell Transplantation for Re..:

Rodríguez-Arbolí, Eduardo ; Othus, Megan ; Orvain, Corentin...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S112 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Validation of mutated CEBPA bZIP as a distinct prognosis en..:

De la Torre, Esther Prados ; Serrano, Josefina ; Martínez-Cuadrón, David...
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
7

Association between Prior Cytotoxic Therapy, Antecedent Hem..:

Orvain, Corentin ; Rodríguez-Arbolí, Eduardo ; Othus, Megan...
Cancers.  15 (2023)  2 - p. 352 , 2023
Link: https://doi.org/10.3390/..
 
?
8

Phase 1/2 study of sorafenib added to cladribine, high-dose..:

Halpern, Anna B. ; Rodríguez-Arbolí, Eduardo ; Othus, Megan...
Blood Advances.  7 (2023)  17 - p. 4950-4961 , 2023
Link: https://doi.org/10.1182/..
 
?
9

Comparison of the 2022 and 2017 European LeukemiaNet risk c..:

Sargas, Claudia ; Ayala, Rosa ; Larráyoz, María J....
Blood Cancer Journal.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
10

PB1779: FLT3-ITD MUTATION CHARACTERIZATION WITH CLASSICAL P..:

Bilbao, Cristina ; Stuckey, Ruth ; Sargas, Claudia...
HemaSphere.  7 (2023)  S3 - p. e93539a0 , 2023
Link: https://doi.org/10.1097/..
 
?
11

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute M..:

Labrador, Jorge ; Martínez-Cuadrón, David ; de la Fuente, Adolfo...
Cancers.  14 (2022)  9 - p. 2342 , 2022
Link: https://doi.org/10.3390/..
 
?
12

Relative impact of residual cytogenetic abnormalities and f..:

Orvain, Corentin ; Wilson, Jacob A. ; Fang, Min...
Haematologica.  108 (2022)  2 - p. 420-432 , 2022
Link: https://doi.org/10.3324/..
 
?
13

Treatment patterns and outcomes of 2310 patients with secon..:

Martínez-Cuadrón, David ; Megías-Vericat, Juan E. ; Serrano, Josefina...
Blood Advances.  6 (2022)  4 - p. 1278-1295 , 2022
Link: https://doi.org/10.1182/..
 
?
14

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Ou..:

Falantes, Jose F. ; Márquez-Malaver, Francisco J. ; Carrillo, Estrella...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  12 - p. e1059-e1066 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Contribution of measurable residual disease status to predi..:

Rodríguez-Arbolí, Eduardo ; Othus, Megan ; Orvain, Corentin...
Haematologica.  108 (2022)  1 - p. 273-277 , 2022
Link: https://doi.org/10.3324/..
 
1-15